Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Personal Services

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The company markets its products through direct ecommerce platform and franchise weight control center channels. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
Website: medifastinc.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates -3.9%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +2.6%. On average the margin is decreasing unsteadily. Gross margin is high, +73.8%. In the last quarter the company beat the estimated EPS, +52.9%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.78 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 15.4% higher than minimum and 89.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.7x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: MED
Share price, USD:  (0.0%)12
year average price 13.08  


year start price 14.91 2025-02-08

max close price 16.21 2025-02-14

min close price 10.40 2026-01-02

current price 12.00 2026-02-07
Common stocks: 10 964 000

Dividend Yield:  0.0%
FCF Yield LTM: 4.6%
EV / LTM EBITDA: 2.0x
EV / EBITDA annualized: 0.9x
Last revenue growth (y/y):  > +200.0%
Last growth of EBITDA (y/y):  +33.3%
Historical revenue growth:  -3.9%
Historical growth of EBITDA:  -34.5%
EV / Sales: 0.1x
Margin (EBITDA LTM / Revenue): 2.6%
Fundamental value created in LTM:
Market Cap ($m): 132
Net Debt ($m): -75
EV (Enterprise Value): 57
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-22zacks.com

Medifast's Q4 Guidance Remains Weak: When Does Growth Return?

2025-12-30zacks.com

Medifast New Product Line Planned: Can Innovation Reignite Demand?

2025-12-24zacks.com

Medifast's Third-Quarter Revenue Fell 36%: Is Stabilization Near?

2025-12-18zacks.com

Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy?

2025-11-03seekingalpha.com

Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript

2025-09-19zacks.com

Will Medifast's Strategic Endeavors Deliver Growth in 2025?

2025-08-04seekingalpha.com

Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript

2025-07-03seekingalpha.com

Medifast: Coach Surge Fuels Growth

2025-05-28zacks.com

Medifast (MED) Up 10.9% Since Last Earnings Report: Can It Continue?

2025-04-21zacks.com

Medifast to Report Q1 Earnings: What Investors Should Expect
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MED MED MED MED MED MED MED MED MED MED MED MED MED MED
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329
fillingDate 2025-11-03 2025-08-04 2024-11-04 2024-08-05 2024-04-29 2023-11-06 2023-08-07 2023-05-01 2022-11-03
acceptedDate 2025-11-03 16:51:10 2025-08-04 16:51:19 2025-02-18 16:50:45 2024-11-04 16:50:52 2024-08-05 16:50:48 2024-04-29 16:51:35 2024-02-20 16:50:57 2023-11-06 16:50:25 2023-08-07 16:50:36 2023-05-01 16:47:31 2023-02-21 16:54:53 2022-11-03 16:51:48 2022-02-23 16:46:46 2021-02-26 14:56:28
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 89M 106M 602M 140M 169M 175M 1 072M 236M 296M 349M 1 599M 390M 1 526M 935M
costOfRevenue 27M 29M 158M 34M 45M 47M 296M 58M 85M 103M 458M 108M 398M 237M
grossProfit 62M 77M 445M 106M 123M 127M 776M 177M 211M 246M 1 140M 283M 1 128M 698M
grossProfitRatio 0.695 0.726 0.754 0.732 0.728 0.752 0.711 0.706 0.725
researchAndDevelopmentExpenses 0 0 0 0 1M 1 000 000 0 1M 0 0 0 0 0 0
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 66M 78M 442M 104M 130M 118M 649M 152M 172M 193M 956M 235M 911M 564M
otherExpenses 0 0 0 0 -4M 2M 0 7000 -51 000 -1000 0 0 0 0
operatingExpenses 66M 78M 442M 104M 131M 119M 649M 152M 172M 193M 956M 235M 911M 564M
costAndExpenses 93M 107M 600M 138M 176M 167M 946M 210M 257M 295M 1 414M 342M 1 310M 801M
interestIncome 1M 1M 5M 1M 1M 0 2M 1M 0 0 0 0 0 246 000
interestExpense 0 0 0 0 0 1M 0 1M 462 000 -181 000 701 000 261 000 0 0
depreciationAndAmortization 3M 4M 13M 3M 3M 4M 13M 3M 3M 3M 11M 3M 7M 4M
ebitda 795 000 3M 16M 5M -5M 12M 140M 29M 42M 56M 196M 51M 223M 138M
ebitdaratio 0.009 0.028 0.038 -0.029 0.07 0.123 0.142 0.162 0.131
operatingIncome -4M -1M 3M 2M -8M 8M 126M 26M 39M 54M 185M 48M 216M 134M
operatingIncomeRatio -0.046 -0.01 0.015 -0.047 0.045 0.108 0.131 0.153 0.123
totalOtherIncomeExpensesNet 1M 4M 909 000 -528 000 -3M 4M 2M 7000 -51 000 -182 000 -747 000 -278 000 -112 000 106 000
incomeBeforeTax -3M 3M 4M 2M -11M 12M 129M 27M 39M 53M 184M 48M 216M 134M
incomeBeforeTaxRatio -0.03 0.027 0.011 -0.063 0.066 0.113 0.132 0.153 0.123
incomeTaxExpense -396 000 395 000 2M 449 000 -2M 3M 29M 3M 9M 13M 40M 12M 52M 31M
netIncome -2M 2M 2M 1M -8M 8M 99M 23M 30M 40M 144M 36M 164M 103M
netIncomeRatio -0.025 0.023 0.008 -0.048 0.048 0.098 0.102 0.115 0.093
eps -0.21 0.23 0.19 0.1 -0.75 0.76 9.1 2.12 2.78 3.68 12.82 3.3 14.01 8.74
epsdiluted -0.21 0.22 0.1 -0.75 0.76 2.12 2.77 3.67 3.27
weightedAverageShsOut 11M 11M 11M 11M 11M 11M 11M 11M 11M 11M 11M 11M 12M 12M
weightedAverageShsOutDil 11M 11M 11M 11M 11M 11M 11M 11M 11M 11M 11M 11M 12M 12M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-23 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 5M 2M -701 000 0 246 000
ebit 3M 126M 185M 216M 134M
nonOperatingIncomeExcludingInterest 0 0 46 000 0 0
netIncomeFromContinuingOperations 2M 99M 144M 164M 103M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 2M 99M 144M 164M 103M
epsDiluted 0.19 9.1 12.73 13.89 8.68

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MED MED MED MED MED MED MED MED MED MED MED MED MED MED
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329
fillingDate 2025-11-03 2025-08-04 2024-11-04 2024-08-05 2024-04-29 2023-11-06 2023-08-07 2023-05-01 2022-11-03
acceptedDate 2025-11-03 16:51:10 2025-08-04 16:51:19 2025-02-18 16:50:45 2024-11-04 16:50:52 2024-08-05 16:50:48 2024-04-29 16:51:35 2024-02-20 16:50:57 2023-11-06 16:50:25 2023-08-07 16:50:36 2023-05-01 16:47:31 2023-02-21 16:54:53 2022-11-03 16:51:48 2022-02-23 16:46:46 2021-02-26 14:56:28
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 100M 102M 91M 115M 108M 97M 94M 113M 147M 124M 88M 70M 104M 164M
shortTermInvestments 74M 61M 71M 55M 55M 59M 56M 45M 0 0 0 0 5M 11M
cashAndShortTermInvestments 174M 163M 162M 170M 164M 156M 150M 158M 147M 124M 88M 70M 110M 174M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 584 000
inventory 23M 30M 42M 40M 40M 46M 55M 58M 69M 97M 119M 145M 180M 53M
otherCurrentAssets 11M 14M 0 15M 21M 17M 0 8M 13M 10M 16M 15M 16M -584 000
totalCurrentAssets 208M 206M 214M 225M 224M 220M 224M 224M 229M 230M 223M 230M 307M 234M
propertyPlantEquipmentNet 41M 43M 49M 51M 53M 66M 67M 69M 71M 73M 76M 78M 81M 38M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 12M 11M 11M 4M 4M 4M 4M 11M 5M 5M 5M 6M 4M 692 000
otherNonCurrentAssets 7M 8M 10M 11M 12M 14M 15M 16M 14M 14M 12M 13M 6M 3M
totalNonCurrentAssets 60M 63M 70M 66M 69M 83M 86M 96M 90M 91M 93M 97M 91M 42M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 268M 269M 284M 291M 294M 303M 310M 320M 319M 322M 316M 326M 398M 276M
accountPayables 41M 40M 23M 66M 69M 71M 39M 103M 105M 113M 53M 0 71M 36M
shortTermDebt 5M 6M 0 6M 12M 6M 0 5M 5M 5M 0 6M 0 0
taxPayables 0 5M 1M 8M 9M 5M 10M 1M 4M 13M 8M 0 3M 3M
deferredRevenue 0 0 316 000 0 -60M -71M 574 000 -103M -101M 0 7M 0 8M 8M
otherCurrentLiabilities 0 -5M 33M -8M -15M 71M 0 105M 105M 13M 0 148M 0 0
totalCurrentLiabilities 47M 46M 64M 72M 75M 77M 92M 110M 115M 132M 141M 154M 170M 111M
longTermDebt 7M 7M 0 12M 26M 15M 0 17M 18M 19M 0 22M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 -13M 0 0 0 0 0 0 15M 0 0
totalNonCurrentLiabilities 7M 7M 10M 12M 13M 15M 16M 17M 18M 19M 20M 22M 26M 7M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 7M 13M 16M 12M 19M 15M 22M 22M 24M 24M 26M 28M 33M 11M
totalLiabilities 54M 53M 74M 84M 88M 92M 108M 127M 133M 151M 161M 176M 196M 119M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 11 000 11 000 11 000 11 000 11 000 11 000 11 000 11 000 11 000 11 000 11 000 11 000 12 000 12 000
retainedEarnings 176M 178M 177M 176M 175M 183M 175M 169M 164M 152M 140M 132M 190M 154M
accumulatedOtherComprehensiveIncomeLoss 220 000 179 000 180 000 349 000 26 000 22 000 248 000 141 000 123 000 33 000 24 000 391 000 111 000 41 000
othertotalStockholdersEquity 38M 37M 31M 30M 28M 24M 22M 19M 19M
totalStockholdersEquity 215M 216M 210M 207M 205M 211M 201M 193M 186M 171M 155M 151M 202M 157M
totalEquity 215M 216M 210M 207M 205M 211M 201M 193M 186M 171M 155M 151M 202M 157M
totalLiabilitiesAndStockholdersEquity 268M 269M 291M 294M 303M 320M 319M 322M 326M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 268M 269M 284M 291M 294M 303M 310M 320M 319M 322M 316M 326M 398M 276M
totalInvestments 74M 61M 71M 55M 55M 59M 56M 45M 0 0 0 0 5M 11M
totalDebt 12M 13M 16M 18M 19M 21M 22M 22M 24M 24M 26M 28M 33M 11M
netDebt -87M -89M -75M -98M -89M -77M -72M -90M -124M -99M -62M -42M -72M -153M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-23 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 584 000
otherReceivables 0 0 0 0 0
prepaids 10M 19M 0 945 000 6M
totalPayables 25M 64M 104M 119M 76M
otherPayables 2M 25M 51M 48M 39M
accruedExpenses 0 22M 24M 36M 25M
capitalLeaseObligationsCurrent 6M 6M 6M 7M 4M
capitalLeaseObligationsNonCurrent 10M 16M 20M 26M 7M
treasuryStock 0 0 -6M 0 -5M
additionalPaidInCapital 33M 27M 22M 12M 8M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MED MED MED MED MED MED MED MED MED MED MED MED MED MED
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329 910 329
fillingDate 2025-11-03 2025-08-04 2024-11-04 2024-08-05 2024-04-29 2023-11-06 2023-08-07 2023-05-01 2022-11-03
acceptedDate 2025-11-03 16:51:10 2025-08-04 16:51:19 2025-02-18 16:50:45 2024-11-04 16:50:52 2024-08-05 16:50:48 2024-04-29 16:51:35 2024-02-20 16:50:57 2023-11-06 16:50:25 2023-08-07 16:50:36 2023-05-01 16:47:31 2023-02-21 16:54:53 2022-11-03 16:51:48 2022-02-23 16:46:46 2021-02-26 14:56:28
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -2M 2M 2M 1M -8M 8M 99M 23M 30M 40M 144M 36M 164M 103M
depreciationAndAmortization 3M 4M 17M 3M 3M 4M 13M 3M 3M 3M 11M 3M 7M 4M
deferredIncomeTax -648 000 -20 000 -7M 106 000 -103 000 112 000 1M -6M 619 000 800 000 -924 000 0 -4M 601 000
stockBasedCompensation 910 000 3M 7M 606 000 2M 2M 8M 3M 3M 606 000 11M 3M 10M 7M
changeInWorkingCapital 9M -11M -10M 1M -984 000 -5M 20M 6M 5M 18M 22M 14M -88M 27M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 297 000
inventory 7M 9M 12M -492 000 7M 8M 64M 11M 28M 22M 61M 12M -127M -5M
accountsPayables -516 000 -13M -35M -4M -4M -16M -36M -3M -10M -22M -38M 0 0 0
otherWorkingCapital 3M -7M 13M 6M -4M 3M -8M -1M -13M 18M -2M 2M 39M 31M
otherNonCashItems 2M -2M 15M 3M 22M 16M 5M 1M 1M 1M 8M -217 000 5M 4M
netCashProvidedByOperatingActivities 12M -3M 24M 9M 13M 7M 148M 30M 43M 64M 195M 55M 95M 145M
investmentsInPropertyPlantAndEquipment -1M -1M -7M -1M -2M -2M -6M -2M -2M -2M -17M -2M -34M -6M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -20M -16M -47M -7M -8M -9M -55M -45M 0 0 0 0 0 0
salesMaturitiesOfInvestments 8M 31M 27M 6M 8M 8M 0 0 0 0 5M 0 5M 5M
otherInvestingActivites 0 0 81 999 -594 000 -934 000 -45M 0 0 0
netCashUsedForInvestingActivites -14M 13M -2M -3M -3M -46M -2M -2M -2M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 0 0 36 000 0 0 0 0
commonStockRepurchased 0 -1000 -836 000 -2000 -16 000 -817 000 -7M -110 000 -2000 -7M -128M -20M -62M -6M
dividendsPaid 0 -1000 -1000 -4000 -710 000 -18M -18M -19M -18M
otherFinancingActivites 0 0 0 0 36 000 -110 000 0 105 000 -7M
netCashUsedProvidedByFinancingActivities 0 -2000 -3000 -20 000 -1M -18M -18M -26M -45M
effectOfForexChangesOnCash 0 0 47 000 4000 28 000 15 000 -72 000 26 000 90 000 9000 -67 000 119 000 112 000 -21 000
netChangeInCash -2M 10M -4M 7M 11M 3M 7M -35M 24M 36M -16M 9M -60M 87M
cashAtEndOfPeriod 100M 102M 91M 115M 108M 97M 94M 113M 147M 124M 88M 70M 104M 164M
cashAtBeginningOfPeriod 102M 92M 94M 108M 97M 94M 88M 147M 124M 88M 104M 61M 164M 77M
operatingCashFlow 12M -3M 24M 9M 13M 7M 148M 30M 43M 64M 195M 55M 95M 145M
capitalExpenditure -1M -1M -7M -1M -2M -2M -6M -2M -2M -2M -17M -2M -34M -6M
freeCashFlow 11M -5M 17M 8M 11M 5M 141M 28M 41M 62M 178M 54M 60M 139M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-23 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 95 000 0 0 0 0
netCashProvidedByInvestingActivities -27M -61M -11M -29M -1M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -836 000 -7M -128M -62M -6M
netCommonStockIssuance -836 000 -7M -128M -62M -6M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -715 000 -73M -72M -64M -53M
commonDividendsPaid -715 000 -73M -72M -64M -53M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 36 000 188 000 0 811 000 2M
netCashProvidedByFinancingActivities -2M -80M -200M -125M -57M
incomeTaxesPaid 0 34M 37M 57M 25M
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-03 ET (fiscal 2025 q3)
2025 q2
2025-08-04 ET (fiscal 2025 q2)
2025 q1
2025-04-28 ET (fiscal 2025 q1)
2024 q4
2025-02-18 ET (fiscal 2024 q4)
2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q2
2024-08-05 ET (fiscal 2024 q2)
2024 q1
2024-04-29 ET (fiscal 2024 q1)
2023 q4
2024-02-20 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-07 ET (fiscal 2023 q2)
2023 q1
2023-05-01 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-02 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-03 16:51 ET
Medifast reported for 2025 q3
SEC form 8
2025-11-03 16:15 ET
Medifast reported for 2025 q3
SEC form 8
2025-11-03 16:15 ET
Medifast published news for 2025 q3
SEC form 10
2025-08-04 20:51 ET
Medifast reported for 2025 q2
SEC form 8
2025-08-04 20:07 ET
Medifast reported for 2025 q2
SEC form 8
2025-08-04 20:07 ET
Medifast published news for 2025 q2
SEC form 10
2025-04-28 20:50 ET
Medifast published news for 2025 q1
SEC form 8
2025-04-28 00:00 ET
Medifast reported for 2025 q1
SEC form 8
2025-04-28 00:00 ET
Medifast published news for 2025 q1
SEC form 10
2025-04-28 00:00 ET
Medifast published news for 2025 q1
SEC form 10
2025-02-18 21:50 ET
Medifast published news for 2024 q4
SEC form 10
2025-02-18 00:00 ET
Medifast published news for 2024 q4
SEC form 8
2025-02-18 00:00 ET
Medifast published news for 2024 q4
SEC form 8
2025-02-18 00:00 ET
Medifast reported for 2024 q4
SEC form 10
2024-11-04 16:50 ET
Medifast reported for 2024 q3
SEC form 10
2024-08-05 16:50 ET
Medifast reported for 2024 q2
SEC form 8
2024-08-05 16:16 ET
Medifast published news for 2024 q2
SEC form 8
2024-08-05 16:16 ET
Medifast reported for 2024 q2
SEC form 10
2024-08-05 00:00 ET
Medifast reported for 2024 q2
SEC form 10
2024-04-29 16:51 ET
Medifast published news for 2024 q1
SEC form 8
2024-04-29 16:36 ET
Medifast reported for 2024 q1
SEC form 8
2024-04-29 16:36 ET
Medifast published news for 2024 q1
SEC form 10
2024-04-29 00:00 ET
Medifast published news for 2024 q1
SEC form 8
2024-02-20 17:23 ET
Medifast reported for 2023 q4
SEC form 8
2024-02-20 17:23 ET
Medifast published news for 2023 q4
SEC form 10
2024-02-20 16:50 ET
Medifast published news for 2023 q4
SEC form 10
2024-02-20 00:00 ET
Medifast published news for 2023 q4
SEC form 10
2023-11-06 16:50 ET
Medifast reported for 2023 q3
SEC form 8
2023-11-06 16:16 ET
Medifast reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Medifast reported for 2023 q3
SEC form 6
2023-08-07 17:15 ET
Medifast published news for 2023 q2
SEC form 10
2023-08-07 16:50 ET
Medifast reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Medifast reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Medifast published news for 2023 q2
SEC form 6
2023-06-20 17:15 ET
Medifast published news for 2023 q1
SEC form 6
2023-06-15 16:17 ET
Medifast published news for 2023 q1
SEC form 10
2023-05-01 00:00 ET
Medifast reported for 2023 q1
SEC form 8
2023-05-01 00:00 ET
Medifast published news for 2023 q1
SEC form 6
2023-03-16 16:20 ET
Medifast published news for 2022 q4
SEC form 10
2023-02-21 16:54 ET
Medifast reported for 2022 q4
SEC form 6
2023-02-21 16:15 ET
Medifast published news for 2022 q4
SEC form 10
2023-02-21 00:00 ET
Medifast reported for 2022 q4
SEC form 8
2023-02-21 00:00 ET
Medifast published news for 2022 q4
SEC form 6
2022-12-08 16:10 ET
Medifast published news for 2022 q3
SEC form 10
2022-11-03 16:51 ET
Medifast reported for 2022 q3
SEC form 6
2022-11-03 16:08 ET
Medifast published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Medifast reported for 2022 q3
SEC form 6
2022-09-08 16:09 ET
Medifast published news for 2022 q2
SEC form 10
2022-08-03 16:45 ET
Medifast reported for 2022 q2
SEC form 6
2022-08-03 16:07 ET
Medifast published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Medifast published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Medifast reported for 2022 q2
SEC form 6
2022-06-16 16:08 ET
Medifast published news for 2022 q1
SEC form 6
2022-06-03 08:31 ET
Medifast published news for 2022 q1
SEC form 6
2022-06-01 08:24 ET
Medifast published news for 2022 q1
SEC form 10
2022-05-02 16:42 ET
Medifast reported for 2022 q1
SEC form 6
2022-05-02 16:09 ET
Medifast published news for 2022 q1
SEC form 8
2022-05-02 00:00 ET
Medifast published news for 2022 q1
SEC form 10
2022-05-02 00:00 ET
Medifast reported for 2022 q1
SEC form 6
2022-04-21 17:17 ET
Medifast published news for 2022 q1
SEC form 6
2022-03-17 16:43 ET
Medifast published news for 2021 q4
SEC form 10
2022-02-23 16:46 ET
Medifast published news for 2021 q4
SEC form 6
2022-02-23 16:30 ET
Medifast published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Medifast published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Medifast published news for 2021 q4
SEC form 6
2021-12-08 16:06 ET
Medifast published news for 2021 q3
SEC form 10
2021-11-04 16:33 ET
Medifast published news for 2021 q3
SEC form 6
2021-11-04 16:12 ET
Medifast published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Medifast published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Medifast published news for 2021 q3
SEC form 6
2021-09-15 19:36 ET
Medifast published news for 2021 q2
SEC form 6
2021-09-13 16:31 ET
Medifast published news for 2021 q2
SEC form 6
2021-09-09 17:16 ET
Medifast published news for 2021 q2
SEC form 6
2021-09-01 17:18 ET
Medifast published news for 2021 q2
SEC form 6
2021-08-05 16:06 ET
Medifast published news for 2021 q2
SEC form 10
2021-08-04 16:25 ET
Medifast published news for 2021 q2
SEC form 6
2021-08-04 16:08 ET
Medifast published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Medifast published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Medifast published news for 2021 q2
SEC form 6
2021-06-03 16:31 ET
Medifast published news for 2021 q1
SEC form 10
2021-05-04 16:30 ET
Medifast published news for 2021 q1
SEC form 6
2021-05-04 16:06 ET
Medifast published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Medifast published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Medifast published news for 2021 q1
SEC form 6
2021-04-19 08:54 ET
Medifast published news for 2021 q1
SEC form 6
2021-04-14 20:51 ET
Medifast published news for 2021 q1
SEC form 6
2021-03-18 16:06 ET
Medifast published news for 2020 q4
SEC form 10
2021-02-26 14:56 ET
Medifast published news for 2020 q4
SEC form 6
2021-02-25 16:06 ET
Medifast published news for 2020 q4
SEC form 6
2021-01-08 10:00 ET
Medifast published news for 2020 q4
SEC form 6
2020-12-10 16:31 ET
Medifast published news for 2020 q3
SEC form 10
2020-11-03 16:50 ET
Medifast published news for 2020 q3
SEC form 6
2020-11-02 16:44 ET
Medifast published news for 2020 q3